Founded in 2015, Gene+ is a genetic testing and precision oncology company dedicated to the development and commercialization of next-generation sequencing products and services. Based on its proprietary sequencing technology, Gene+ offers a range of comprehensive genomic profiling assays to identify the genetic alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials using fully automatic bioinformatic analysis, interpretation and report generating system. With its CAP-accredited, EMQN-accredited and ISO-accredited clinical laboratories, Gene+ has been able to serve its customers with the highest standards and best quality, accumulating more than 400,000 samples tested. Using big data platform of cancer genomics, Gene+ has developed a deep cooperation and connection with its partners ranging from biotechs, biopharmas to research institutes, including MD Anderson Cancer, Duke University, BeiGene, and AstraZeneca etc, with more than 400 collaboration projects in scientific research and clinical application and more than 230 publications in Science, Nature Genetics, Nature Medicine, etc. For more information, please visit our website at en.geneplus.cn or contact us at global.service@geneplus.org.cn.